ReNeuron Group

ReNeuron Group (AIM: RENE)

Currency in GBP

Last close As at 21/09/2023

GBP0.07

▲ −0.75 (−9.68%)

Market capitalisation

GBP4m

Overview
Price performance
Financials
Research
Sector insights
Thematics

UK-based ReNeuron Group is focused on its stem cell-derived exosome drug delivery platform, CustomEx. The company is progressing the preclinical development of exosome-based therapeutics utilising its CustomEX technology.

Drug delivery remains a major challenge in both central nervous system (CNS) and cell and gene drug development, and we view these as key markets for ReNeuron to target with its exosome drug delivery platform. Additionally, ReNeuron’s diversification in exosome-producing stem cell lines and its ability to produce exosomes with enhanced natural tissue-targeting affinity, particularly neural stem cell lines to target CNS indications, may offer market differentiation against single cell line competitors.

Latest Insights

Healthcare |
Flash note

15.09.23

ReNeuron Group — A step forward on the Exosome delivery platform

Healthcare |
Update

30.05.23

ReNeuron Group — Full steam ahead with CustomEx

Flash note

09.12.22

ReNeuron Group — Encouraging data for iPSCs opens potential

Healthcare |
Update

06.12.22

ReNeuron Group — Pushing on with CustomEx in H123

Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

Ian Ross

Chairman
John Hawkins

CFO
John Sinden

Chief Scientific Officer

Balance Sheet

Forecast net cash (£m)

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(28.2)	(24.3)	(74.1)
Relative	(31.6)	(24.7)	(75.2)
52 week high/low	28.5p/5.8p

Financials

ReNeuron Group has generated in vivo data for CustomEX, marking a key step towards validating its proprietary stem cell-derived exosome platform. While the precise nature of the data is yet to be disclosed, we view the update as an encouraging sign and believe that it could improve traction for discussions for collaborations and partnerships, a key near-term goal for the company. ReNeuron now aims to broaden its capabilities by focussing on the functional delivery of specific therapeutics payloads, which we believe could include siRNA, mRNA, proteins, small molecules and genes, based on previous studies. Updates are expected in due course, potentially representing an important catalyst for investor attention, provided the data continue to be positive.